Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Comment by davikingon Jun 25, 2017 12:08pm
135 Views
Post# 26402532

RE:RE:Let's talk the untold interim analysis & selling debacle

RE:RE:Let's talk the untold interim analysis & selling debacleJust a reminder of who BoyGeorge/Schemehatcher/SWYG/MM et al really started as:
_________________________________________________________
March 10, 2016 - 06:12 PM 
Post# 24645772

RE:Hmmm 300 000 at 3:30

lol

you forgot no hope!

This looks like it could go straight to zero without passing go

if the fda say no...say good bye to your dough

say that 10 times slow with your account in front of you

jus sayin

gsl
March 10, 2016 - 06:31 PM 
Post# 24645842
     
 

mercedesman is a pro-plant

way too much info and way too positive

I can see a pumper-poster 30' from my monitor

gsl
________________________________________________________________________
 

I signed up to challenge the pumper  March 11, 2016 - 09:10 AM

So, VWboy where do you get all your numbers from.  why is it that professional analysts have targets of $1 or $2 on this whoofer and are selling the stock on any rise.  I have only seen the house with the biggest target , mackie, sell the stock since they put on a report for all pros to see.  If this was the real deal and they had a $2 target on the stock why is there no buying and why have they sold way over 100 thou since the report was public and bought not 1, thats right vwboy not 1 share since they wrote it up

simple question and I look forward to a timely reply since you always seem to be hanging around and ready to present your fascinating array of number trickery....do you do tie balloons and do card tricks at kids bday partys on the weekend...give me a break

gsl

March 12, 2016 - 10:18 AM 
Post# 24651341
 

RE:PERSONAL SPECTRAL COVERAGE AND TARGET PRICE

nice try and good luck with that fda approval, youve been at it now for 7 years

I suggest a full blown effort to educate yourself on CTSO which trades on a real exchange here in the US and is already approved in europe and selling over 4 million in filters annually.  better yet, look at the 5 US investment analysts that have a consenus $18 handle on the 1 year target.  read the zacks report where it is clear that cytosorb is fast becoming the standard of care in many german hospitals.  zacks also suggests that ctso is set for approval in many new countrys including CANADA....a good chance that CTSO will be approved in CANADA before the struggling 62 cent canadian company gets approval in their own backyard.  how much longer do you need to stay with a 62 cent company when you can buy a approved $5 company on NASDAQ that has a consenus $18 target with a high of $25 from one professional at Brean.  the only analyst on this company Mackie, has sold 150 thou since the last financing and not bought one share.  be careful here cause if the fda says NO...youll lose your dough!! the facts are pointing to a delayed trial or maybe even a outright NO, as the volume and interest on this stock is so low it is almost funny.  the US listing of this company never trades, US investers with real knowlege of medical stocks are NOT interested...period

gsl

 

Bullboard Posts